$RLFTF NEURORX AND RELIEF ANNOUNCE INITIAL SUCCESSFUL RESULTS FROM EXPANDED ACCESS USE OF RLF-100™ (AVIPTADIL) IN PATIENTS WITH CRITICAL COVID-19 AND SEVERE COMORBIDITY: 72% SURVIVAL SEEN IN ICU PATIENTS
https://relieftherapeutics.com/newsblog/neuro...u-patients